Equillium (EQ) Competitors $1.38 -0.08 (-5.48%) Closing price 04:00 PM EasternExtended Trading$1.42 +0.05 (+3.26%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. LYEL, MREO, NMRA, ALEC, GALT, SCPH, TECX, ACB, JBIO, and IMMPShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Lyell Immunopharma (LYEL), Mereo BioPharma Group (MREO), Neumora Therapeutics (NMRA), Alector (ALEC), Galectin Therapeutics (GALT), scPharmaceuticals (SCPH), Tectonic Therapeutic (TECX), Aurora Cannabis (ACB), Jade Biosciences (JBIO), and Prima BioMed (IMMP). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Its Competitors Lyell Immunopharma Mereo BioPharma Group Neumora Therapeutics Alector Galectin Therapeutics scPharmaceuticals Tectonic Therapeutic Aurora Cannabis Jade Biosciences Prima BioMed Equillium (NASDAQ:EQ) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Do insiders & institutionals hold more shares of EQ or LYEL? 27.1% of Equillium shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 30.3% of Equillium shares are held by insiders. Comparatively, 22.3% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend EQ or LYEL? Equillium presently has a consensus target price of $1.00, suggesting a potential downside of 27.54%. Lyell Immunopharma has a consensus target price of $15.00, suggesting a potential downside of 13.39%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67Lyell Immunopharma 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 Which has better earnings & valuation, EQ or LYEL? Equillium has higher revenue and earnings than Lyell Immunopharma. Equillium is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$41.10M2.00-$8.07M-$0.56-2.46Lyell Immunopharma$60K5,545.58-$342.99M-$24.29-0.71 Is EQ or LYEL more profitable? Equillium has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -552,328.31%. Lyell Immunopharma's return on equity of -85.58% beat Equillium's return on equity.Company Net Margins Return on Equity Return on Assets EquilliumN/A -139.56% -90.56% Lyell Immunopharma -552,328.31%-85.58%-68.85% Does the media refer more to EQ or LYEL? In the previous week, Equillium and Equillium both had 1 articles in the media. Equillium's average media sentiment score of -1.00 equaled Lyell Immunopharma'saverage media sentiment score. Company Overall Sentiment Equillium Negative Lyell Immunopharma Negative Which has more risk and volatility, EQ or LYEL? Equillium has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. SummaryEquillium beats Lyell Immunopharma on 7 of the 13 factors compared between the two stocks. Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.11M$3.44B$6.12B$10.63BDividend YieldN/A2.27%5.72%4.85%P/E Ratio-2.4623.2229.2227.22Price / Sales2.00271.03491.97186.54Price / CashN/A45.2825.8230.35Price / Book2.5610.6612.476.66Net Income-$8.07M-$52.56M$3.31B$276.04M7 Day Performance11.29%4.95%1.86%0.01%1 Month Performance-5.48%16.47%8.42%3.60%1 Year Performance23.21%14.84%63.51%32.71% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium0.4729 of 5 stars$1.38-5.5%$1.00-27.5%+29.2%$82.11M$41.10M-2.4640Short Interest ↑LYELLyell Immunopharma0.9213 of 5 stars$16.83+1.9%$15.00-10.9%-22.9%$317.18M$60K-0.69270Positive NewsShort Interest ↑Gap UpMREOMereo BioPharma Group1.9805 of 5 stars$2.00+2.0%$7.40+270.0%-51.5%$311.64M$10M-28.5740Gap UpNMRANeumora Therapeutics2.0031 of 5 stars$1.86-1.6%$7.14+284.0%-89.0%$306.08MN/A-1.18108ALECAlector4.0652 of 5 stars$3.04+0.7%$4.17+37.1%-33.7%$305.66M$100.56M-2.62270Positive NewsGap DownTrading HaltedGALTGalectin Therapeutics1.2044 of 5 stars$5.10+8.1%$6.00+17.6%+90.6%$302.36MN/A-7.979News CoverageSCPHscPharmaceuticals3.7754 of 5 stars$5.67flat$7.78+37.3%N/A$302.20M$49.97M-3.1330TECXTectonic Therapeutic2.3292 of 5 stars$16.09+0.4%$80.29+399.0%-49.1%$299.77MN/A-3.98120News CoverageAnalyst ForecastACBAurora Cannabis0.5412 of 5 stars$5.40+1.9%N/A-4.7%$297.98M$246.72M-28.421,130JBIOJade Biosciences2.0074 of 5 stars$9.09+0.1%$19.00+109.0%N/A$296.25MN/A-0.3020Gap DownIMMPPrima BioMed0.7305 of 5 stars$1.99-1.0%$7.00+251.8%+2.5%$295.86M$6.69M0.002,021News Coverage Related Companies and Tools Related Companies Lyell Immunopharma Competitors Mereo BioPharma Group Competitors Neumora Therapeutics Competitors Alector Competitors Galectin Therapeutics Competitors scPharmaceuticals Competitors Tectonic Therapeutic Competitors Aurora Cannabis Competitors Jade Biosciences Competitors Prima BioMed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EQ Stock Alerts